ClinicalTrials.gg
CompletedNCT02614404MIMUpdated Feb 11, 2021

Effect of Imatinib on Suppression of Malaria Parasites in Patients With Uncomplicated Plasmodium Falciparum Malaria

A Phase 1 interventional study of Imatinib combination therapy and Dihydroartemisinin-piperaquine in Plasmodium Falciparum Malaria, sponsored by HuLow. Completed at 1 site in Vietnam. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2021-02-11.

Sponsored by HuLow · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
15
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies in Malaria, Falciparum with a site in Vietnam — none open to participants now, none under way, none of them phase 3. Malaria, Falciparum · Vietnam.

Enrollment
10th of 10
15 · median 486
Started
2015
with 1 other
Phase 1
Only one
of the 11
Registered
7th of 11
by date
Lead sponsor
1 of 11
HuLow

Among the 11 studies in Malaria, Falciparum with a site in Vietnam, this one is the 10th largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2015, is the only one in phase 1, and was the 7th registered.

Malaria, Falciparum

456 studies on the registry are indexed under Malaria, Falciparum; 38 are open to participants now.

Browse Malaria, Falciparum studies →

Open to participants now

None of the 11 studies in Malaria, Falciparum with a site in Vietnam is open now. The open studies under Malaria, Falciparum, anywhere →

Who these studies take

Of the 22 Malaria, Falciparum studies recruiting now, 6 (27%) set no upper age limit and 15 (68%) stop at 75 or younger; 14 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Malaria, Falciparum with a site in Vietnam as a file.
02

Study summary

The purpose of this study is to determine the efficacy and safety of imatinib in combination with dihydroartemisinin plus piperaquine in the treatment uncomplicated P. falciparum malaria in adult male patients.

Read the detailed description

An exploratory study to examine the efficacy and safety of imatinib mesylate in combination with dihydroartemisinin plus piperaquine on suppression of parasitemia in patients with uncomplicated Plasmodium falciparum malaria. In vitro studies of P. falciparum parasitized erythrocytes demonstrate that inhibitors of the protein tyrosine kinase SYK prevent malaria parasite egress from infected red blood cells and thereby terminate the parasite's life cycle. Although no potent syk kinase inhibitors were approved for human use at the time of initiation of this study, a bcr-abl tyrosine kinase inhibitor (imatinib mesylate (Gleevec®)) that also exhibits off-target inhibition of syk tyrosine kinase, has been FDA-approved for treatment of a number of human malignancies including chronic myelogenous leukemia and GIST. Because imatinib can be taken daily for many years without significant toxicity, it can be used to obtain a preliminary indication of whether inhibition of erythrocyte syk kinase can suppress parasitemia in patients with P. falciparum malaria. In a phase 1 clinical trial on the same patient population, anti-malaria activity was observed with imatinib, with little or no accompanying toxicity. Because dihydroartemisinin plus piperaquine constitute the currently used standard-of-care therapy for malaria in Southeast Asia, the above trial will test the safety and efficacy of the combination of imatinib plus dihydroartemisinin and piperaquine in treatment of uncomplicated malaria. In this pilot study, the rate of decrease in peripheral blood parasitemia in 30 adult male patients with uncomplicated malaria will be compared to the same rate of decrease in parasitemia in 30 adult male patients treated solely with dihydroartemisinin plus piperaquine.

03

Conditions studied

  • Plasmodium Falciparum Malaria

Browse trials for

Keywords

  • Plasmodium falciparum
  • Uncomplicated malarial
  • imatinib mesylate
  • antimalarials
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Gender: only adults are selected for the trial; note that female subjects cannot be women of child-bearing age.
  • Age: 18-50 years.
  • Target disease: Uncomplicated Plasmodium falciparum malaria

Exclusion criteria

Exclusion Criteria:

  • symptoms and signs of complicated malaria
  • including continuous high fever of over 390C, psychiatric disorders, confusion, other neurological symptoms, symptoms and signs of functional impairment of the organs such as lungs, kidneys or cardiovascular system;
  • symptoms and signs of liver damage or kidney damage
  • symptoms and signs of another complicating infection such as pneumonia, dengue fever, and other bacterial infection.
  • P. falciparum > 25.000 / mm3
  • WBC \<4000 and >10.000 /mm3

    • RBC \< 3.5x106/mm3
    • \< 40.000 /mm3
  • \< 10 g/dL
  • more than 200% of the upper limit (56 units/L)
  • AST more than 200% of the upper limit (40 units/L)
  • Blood creatine more than 75% of the upper limit (men: 1.2 mg/dL, women 1 mgdL)
  • Serum total protein \< 6 g/L
  • Glycemia \< 50 mg/dL> 200 mg/dL
  • Standard urine test Serious alterations
  • Concomitant treatments

Antimalarial Drugs Anticoagulant therapy

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Imatinib combination therapy

    Administration of imatinib (400 mg/day) plus dihydroartemisinin (40 mg/day) plus piperaquine (320 mg/day) to uncomplicated adult male malaria patients. Normal health parameters will be monitored continuously to evaluate safety and the decrease in peripheral blood parasitemia with time will be quantitated to assess efficacy.

    Drug: Imatinib combination therapy

  • Active comparator
    dihydroartemisinin plus piperaquine

    Administration of dihydroartemisinin (40 mg/day) plus piperaquine (320 mg/day) to uncomplicated adult male malaria patients. Normal health parameters will be monitored continuously to evaluate safety and the decrease in peripheral blood parasitemia with time will be quantitated to assess efficacy.

    Drug: Dihydroartemisinin-piperaquine

Interventions

  • DrugImatinib combination therapy

    Drug page: Imatinib

    Imatinib plus dihydroartemisinin plus piperaquine

    Also known as: Gleevec, Glivec

  • DrugDihydroartemisinin-piperaquine

    Drug pages: Artenimol · Piperaquine

    Standard of care

    Also known as: Artekin, Eurartesim, Diphos, Timequin, Duocotecxin, Malacur, Ridmal

06

What researchers measure

Primary outcomes

  1. Time to Parasite Clearance

    Parasite clearance was determined by assessing the parasite count in blood, using thin film, thick film and qPCR analysis

    Time frame: From baseline to the time point when the blood parasite count is zero (up to a maximum of 5 days)

  2. 28-day Cure Rate

    28-day cure rate was defined as the percentage of participants with blood parasite count of zero after 28 days of treatment and no evidence of recurrent infection with the same parasite genotype after reduction of the asexual parasitemia. Follow up after treatment will only be performed in the case of complete clearance of parasites at D5 due to Imatinib treatment.

    Time frame: Day 28

Secondary outcomes

  1. Frequency of adverse events

    Adverse events (AEs) are defined as events possibly related to the study drug as judged by physician that occur within 1 week of beginning treatment with imatinib. 1. Incidence, severity, drug-relatedness, seriousness of adverse events 2. Laboratory values (biochemistry and haematology) 3. Vital signs

    Time frame: Within 1 week of beginning treatment with imatinib

07

Study locations

1 site
  • A Tuc
    Huong Hoa, Quang Tri 520000, Vietnam
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2015 to primary completion in Dec 2016, 13 months.

Of 49 phase 1 interventional studies under Malaria, Falciparum, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 18. This study's 13 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2015
First posted
Nov 25, 2015
StartActual
Nov 2015
Primary completionActual
Dec 2, 2016
CompletionActual
Feb 2, 2017
Last update
Feb 11, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 11, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02614404
Lead sponsor
HuLow
Collaborators
Purdue University, University of Turin, Italy, Università degli Studi di Sassari, Hue University
Responsible party
Sponsor
First posted
Nov 25, 2015
Start date
Nov 2015
Primary completion
Dec 2, 2016
Completion
Feb 2, 2017
Last update
Feb 11, 2021

Study contacts

Huynh D Chien, MD, PhD
principal investigator · Hue University
Francesco M Turrini, MD, PhD
principal investigator · University of Turin, Italy
Philip S Low, PhD
principal investigator · Purdue University

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Imatinib

Start the discussion